[ Beijing, Feb 27, 2018] ---R&D-Based Pharmaceutical Association Committee (RDPAC) today announced that Madam KANG Wei will take the role of Managing Director of RDPAC, effective 26th February, 2018. She will be based in Beijing and will report directly to the RDPAC Executive Committee.
In her role, KANG Wei will lead the RDPAC office team to implement the RDPAC vision of being a valued partner in delivering the goals of “Healthy China”: to improve the health and quality of life of the people in China. She will oversee the implementation of RDPAC strategic imperatives in the following areas: science & regulatory; pricing & reimbursement; provincial market access; business integrity & compliance; communication and alliances.
KANG Wei is a seasoned expert who brings almost 30 years of experience working in the pharmaceutical industry in China. She started her career as a medical representative at Xian-Janssen and from there on took roles with increasing responsibilities. Prior to joining RDPAC, she held the positions of Vice President and BU Head at Fresenius-Kabi and Great China Senior Marketing Director and Co-leading & Acting BU head at Novartis.
“I am confident the Executive Committee made the right choice in appointing KANG Wei as RDPAC Managing Director. Her experience and in-depth knowledge of our industry will be great assets to deliver RDPAC objectives – accelerate innovation, improve access, exemplify business integrity, build image and collaborate – both in and outside China,” Jean-Christophe Pointeau, Chairman, RDPAC and Country Chair of Sanofi China said.
###
